MK Series SARMs: Advanced Tools for Exploring Muscle Protection and Tissue-Selective Research
In the field of selective androgen receptor modulator research, MK series compounds (such as MK-0773 and MK-4541) represent significant progress from muscle health studies to tissue-specific therapeutic exploration. MK-0773, a steroidal SARM that has entered Phase II clinical studies, provides a reference model for sarcopenia and osteoporosis research from preclinical to clinical stages. MK-4541 demonstrates potential in research for differentially modulating muscle anabolism and prostate tissue. PHMO supports your complete research pipeline from basic science to translational medicine with high-purity, compliant research materials.
With in-depth research into tissue-selective androgen modulation mechanisms, scientists are committed to identifying compounds that can promote muscle and bone health while reducing the side effects associated with traditional hormone therapies. The MK series SARMs emerged in this context, with research data spanning from preclinical models to early clinical trials, providing important tools for understanding the selective effects of SARMs in different tissues. These products are strictly controlled experimental compounds for research use only, not for human or consumer use.
1. Function & Core Research Applications
l MK-0773 (CAS 606101-58-0) is a steroidal selective androgen receptor modulator shown in research to enhance muscle mass and potentially benefit bone health. Preclinical and early clinical data indicate that MK-0773 can be used in research models for sarcopenia (e.g., age-related or disease-induced muscle loss) and osteoporosis. In Phase II clinical trials conducted, the studied dosage for female sarcopenia was approximately once-daily oral administration, with specific doses varying by study design and for reference only. Due to its relatively defined clinical research path, this compound is often used as a reference tool for evaluating the muscle-protective effects of SARMs.
l MK-4541 (CAS 796885-38-6) is a non-steroidal SARM with high tissue selectivity. Its research focuses not only on promoting muscle anabolism but also on exploring differential agonist/antagonist activity in prostate tissue, making it potentially useful in composite research models of muscle atrophy and prostate cancer-related cachexia. Preclinical studies show that MK-4541 can promote muscle protein synthesis without stimulating—or even while inhibiting—prostate hyperplasia, offering a unique perspective for studying tissue-selective mechanisms. Research doses are mostly based on animal models (e.g., mg/kg/day), and no human dosage has been established.
Note: All MK series products supplied by PHMO are strictly for in vitro or preclinical research use. Not for human, diagnostic, or therapeutic use.
2. Differentiating Features & Advantages
Compared to earlier SARMs, the MK series offers more diverse research pathways, particularly notable in clinical translation and exploration of tissue-selective mechanisms. MK-0773, having entered Phase II clinical trials, provides researchers with a bridge from animal models to human data, aiding in understanding SARM effects in environments closer to human physiology. MK-4541 highlights another dimension of "tissue selectivity"—differential effects on different tissues (e.g., muscle anabolism vs. prostate anti-hyperplasia) under the same receptor regulation. This offers new avenues for developing research tools targeting specific conditions (e.g., cancer cachexia with prostate comorbidity). Both compounds are orally active, facilitating experimental dosing design.
3. Target Audience & Market Validation
This series primarily targets pharmaceutical companies, biotech firms, and academic institutions engaged in muscle metabolism, geriatric medicine, cancer cachexia, and osteoporosis research. MK-0773 has preliminary clinical data support and holds recognition and reference value in the field of sarcopenia drug development. MK-4541 attracts attention in supportive cancer care and tissue-selective pharmacology research due to its unique dual mechanism of action. The global SARMs research market continues to grow, especially in translational medicine and precision therapy research. With their preclinical and early clinical data, the MK series has become an important reference compound in many R&D projects. It is re-emphasized that all products are for research use only.
From mechanistic studies to translational exploration, reliable research materials are the foundation of scientific discovery. PHMO provides a strict Certificate of Analysis (COA) for every batch of MK series products, ensuring the accuracy and reproducibility of your research data. Contact us for product details and quotations, or comment below to share your research directions and needs. PHMO — Your Trusted Research Material Partner!